Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
CLL is a smart cancer, but we are smarter. Dr. Tam at ASH 2019 talks about the outstanding results of the CAPTIVATE trial combining two great drugs, namely ibrutinib and venetoclax.
SWOG, formerly known as the Southwest Oncology Group, is a well-respected National Cancer Institute (NCI) supported organization that conducts and funds clinical trials in many adult cancers. NCI’s National Clinical Trials
The ECOG (E1912) Phase III, randomized, open label, clinical trial, comparing the efficacy of combination ibrutinib and rituximab with standard chemo-immunotherapy (FCR in patients 70 years of age or younger with previously untreated CLL) was a huge game-changer for CLL patients. We are happy to share with you Dr. Koffman’s ASH 2019 interview with Dr. Neil Kay showing that five-year data continue to yield evidence of the superiority of ibrutinib to chemoimmunotherapy for most CLL patients. To understand the powerful impact of this evidence on best practice and learn the subtleties, click here.
ASH 2019 Drs. Brian Koffman and Richard Furman discuss the effectiveness and tolerability of covalent irreversible BTK inhibitors such as acalabrutinib, ibrutinib, and zanubrutinib, as well as non-covalent, reversible (3rd generation) BTK inhibitors such as vecabrutinib, LOXO 305, and ArQule 561.
During this ASH 2019 interview, Dr. Anthony Mato discusses data he presented on LOXO-305. This selective, reversible (non-covalent) BTK inhibitor offers the potential advantage of continuing to be able to block the BTK pathway even when it has mutated, leading to resistance to the approved BTK inhibitors ibrutinib and acalabrutinib.
This is good news for CLL patients as measurement for MRD (minimal or measurable residual disease) is increasingly being recognized as an important data point in treatment decisions for some limited
ASH 2019: Dr. Paul Barr on the combination of umbralisib, ublituximab, and venetoclax for treatment of chronic lymphocytic leukemia (CLL)
At ASH 2019, Dr. Brian Koffman interviewed Dr. Nitin Jain about recent results from a clinical trial testing the combination of the highly effective targeted therapies ibrutinib (a BTK inhibitor) and venetoclax (a BCL2 inhibitor) in previously untreated patients with CLL. In the latter part of the interview, Dr. Jain mentions that achieving MRD negativity may be the best predictor of long-term outcomes.
In this article, Dr. Brian Koffman explains his ASCO 2020 Top Pick #10. This abstract presents the initial results of a multi-center, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax.
One click to our most popular content.
